Pancreatic Cancer Research

ResearcherYokohama City University HospitalActive in the last 2 years

Yuichiro Tozuka

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5051855941. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Peritoneum carcinomatosis as a favourable prognostic factor for treatment with nanoliposomal irinotecan and fluorouracil plus leucovorin in advanced pancreatic… Co-author DOI 10.1177/17588359251351540↗
  2. Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study. Co-author DOI 10.1007/s10147-023-02432-9↗
  3. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational… Co-author DOI 10.1186/s12885-023-10654-3↗
  4. Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus … Co-author DOI 10.3892/ol.2022.13495↗
  5. A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001484↗
  6. Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy. Co-author DOI 10.1111/cas.14245↗
  7. Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis. Co-author DOI 10.1007/s12328-019-00976-w↗
  8. Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pa… Co-author PMID 30416859↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shin Maeda · 7 shared papers, 2018–2025 · strength 0.99
  2. Makoto Ueno · 6 shared papers, 2018–2025 · strength 0.89
  3. Satoshi Kobayashi · 5 shared papers, 2020–2025 · strength 0.82
  4. Shun Tezuka · 5 shared papers, 2018–2025 · strength 0.68
  5. Manabu Morimoto · 5 shared papers, 2018–2024 · strength 0.67
  6. Junji Furuse · 3 shared papers, 2023–2025 · strength 0.60
  7. Shuhei Nagashima · 2 shared papers, 2023–2024 · strength 0.38
  8. Masaaki Murakawa · 1 shared paper, 2025 · strength 0.22
  9. Naoto Yamamoto · 1 shared paper, 2025 · strength 0.22
  10. Shinichi Ohkawa · 2 shared papers, 2018–2022 · strength 0.21
  11. Takashi Kaneko · 2 shared papers, 2019–2020 · strength 0.18
  12. Makoto Sugimori · 2 shared papers, 2018–2020 · strength 0.16
  13. Hiroyuki Asama · 1 shared paper, 2022 · strength 0.13
  14. Soichiro Morinaga · 1 shared paper, 2022 · strength 0.13
  15. Ikuhiro YAMADA · 1 shared paper, 2020 · strength 0.08
  16. Takashi Sasaki · 1 shared paper, 2020 · strength 0.08
  17. Kumiko Umemoto · 1 shared paper, 2020 · strength 0.08
  18. Shuichi Mitsunaga · 1 shared paper, 2020 · strength 0.08
  19. Mitsuhito Sasaki · 1 shared paper, 2020 · strength 0.08
  20. Masafumi Ikeda · 1 shared paper, 2020 · strength 0.08
  21. Masato Ozaka · 1 shared paper, 2020 · strength 0.08
  22. Hiroshi Imaoka · 1 shared paper, 2020 · strength 0.08
  23. Naoki Sasahira · 1 shared paper, 2020 · strength 0.08
  24. Masatsugu Nagahama · 1 shared paper, 2020 · strength 0.08
  25. Yoshimasa Suzuki · 1 shared paper, 2020 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.